Archives     Advertise     Editorial Calendar      Advertiser Index     Subscribe     Contact Us    


AMA Adopts New Policy to Better Diagnose and Treat Long-haul COVID-19


 

With millions of people in the United States experiencing post-acute sequelae of SARS-CoV-2 infection (PASC), also known as long-haul COVID, and millions more expected to suffer from the condition, the American Medical Association (AMA) adopted policy during the Special Meeting of its House of Delegates aimed at improving the assessment, diagnosis, and awareness of post viral syndromes.

Specifically, the new policy calls for the AMA to advocate for legislation to provide funding for research, prevention, control, and treatment of post viral syndromes and long-term sequelae associated with viral infections, such as COVID-19. Under the policy, the AMA will provide physicians and medical students with accurate and current information on post-viral syndromes and collaborate with other medical and educational entities to promote education among patients about post viral syndromes--helping minimize the harm and disability current and future patients face.

"There is much we still don't know about COVID-19 and while many people with COVID-19 recover in the weeks following illness, we're seeing patients experiencing symptoms that either last, or appear, many weeks or months after becoming infected," said AMA Board Member Sandra Adamson Fryhofer, M.D. "Yet, our country currently lacks the necessary resources to adequately support and provide expert care to patients with long-haul COVID. That's why we must continue following the science and conducting research so we can better understand the short and long-term health impacts of this novel illness."

The new policy aims to improve the clinical definitions of post viral syndromes and identify the evidence necessary to appropriately assess all conditions and organ systems affected, as well as the associated behavioral health conditions. According to recent publications, 10-30% of individuals who had COVID-19 reported at least one persistent symptom six months after their infection was cleared. Individuals with long-haul COVID may experience varied and chronic symptoms including neurologic, cognitive, cardiopulmonary, constitutional, musculoskeletal, psychiatric, and mobility impairments. Ongoing and future long-haul COVID research results, that are inclusive of all populations, including people with disabilities and underlying health conditions, are needed in real-time to support providers through rapid development and widespread dissemination of best practices for long-haul COVID care.

 
Share:

Related Articles:


Recent Articles

AACR Establishes New Cancer Evolution Working Group

The American Association for Cancer Research (AACR) announced the formation of its seventh and newest scientific working group, which will be dedicated to supporting cancer evolution research.

Read More

Global Dementia Cases Forecasted To Triple By 2050

New analysis shows a decrease in prevalence due to education countered by increase due to heart health risk factors

Read More

Blackburn, Feinstein Introduce Bill to Protect Access to Breast Cancer Screenings

U.S. Senators Marsha Blackburn (R-Tenn.) and Dianne Feinstein (D-Calif.) today introduced the Protecting Access to Lifesaving Screenings (PALS) Act of 2021, a bill to preserve coverage for routine breast cancer screening for women beginning at age 40.

Read More

CUMBERLAND PHARMACEUTICALS REPORTS 2.5M PATIENT DOSES DELIVERED, NO PRODUCT RECALLS, NO FDA ISSUES IN 2020

The company's 2020 sustainability report highlights its commitment to environmental, social and governance (ESG) activities

Read More

Mobile Mentor Named Winner of Microsoft's 2021 Partner of the Year for Modern Endpoint Management

Mobile Mentor announced they have been awarded the 2021 Global Partner of the Year Award for Modern Endpoint Management.

Read More

Alzheimer's Association Welcomes CMS Announcement of National Coverage Determination Analysis on Treatment for Alzheimer's Disease

On behalf of all those living with Alzheimer's disease, their caregivers, and their families, we appreciate the Centers for Medicare & Medicaid Services (CMS) thoughtful consideration on coverage considerations for monoclonal antibodies targeting amyloid for the treatment of Alzheimer's disease, including aducanumab, which was recently approved by the Food and Drug Administration (FDA).

Read More

HCTec Acquires Talon Healthy IT Services

Healthcare IT firm adds industry-leading help desk service company to portfolio of solutions

Read More

The Seven Steps of Revenue Cycle for a Healthcare Practice

Revenue cycle management tracks patient revenue from the initial encounter with the healthcare system to payment of balance. Getting the seven steps of revenue cycle right helps providers avoid missteps that are costly to the bottom line.

Read More

Expanding Evidence-Based Care for Dementia

The Alzheimer's Association is on a mission to ensure care professionals have access to evidence-based training to ensure those with dementia receive quality care across all settings.

Read More

A Natural Leader

Nashville physician Dr. Ryan Mire to head nation's largest medical-specialty society.

Read More

Email Print
 
 

 

 


Tags:
None
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: